vs
Perimeter Solutions, Inc.（PRM）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Perimeter Solutions, Inc.的1.2倍（$127.1M vs $102.8M），Perimeter Solutions, Inc.同比增速更快（19.2% vs 17.1%），Perimeter Solutions, Inc.自由现金流更多（$11.6M vs $-26.7M），过去两年Perimeter Solutions, Inc.的营收复合增速更高（31.9% vs 20.8%）
Perimeter Solutions是一家以色列云与网络安全企业，专为各类机构打造基于零信任架构的安全远程网络方案，其技术可替代VPN、防火墙等传统安全硬件设备，助力企业简化网络安全部署，提升远程访问的安全性与效率。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
PRM vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.2倍
$102.8M
营收增速更快
PRM
高出2.0%
17.1%
自由现金流更多
PRM
多$38.3M
$-26.7M
两年增速更快
PRM
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $102.8M | $127.1M |
| 净利润 | $-140.2M | — |
| 毛利率 | 45.2% | 51.0% |
| 营业利润率 | -160.7% | -54.6% |
| 净利率 | -136.5% | — |
| 营收同比 | 19.2% | 17.1% |
| 净利润同比 | -197.3% | — |
| 每股收益（稀释后） | $-0.89 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRMZLAB
| Q4 25 | $102.8M | $127.1M | ||
| Q3 25 | $315.4M | $115.4M | ||
| Q2 25 | $162.6M | $109.1M | ||
| Q1 25 | $72.0M | $105.7M | ||
| Q4 24 | $86.2M | $108.5M | ||
| Q3 24 | $288.4M | $101.8M | ||
| Q2 24 | $127.3M | $100.1M | ||
| Q1 24 | $59.0M | $87.1M |
净利润PRMZLAB
| Q4 25 | $-140.2M | — | ||
| Q3 25 | $-90.7M | $-36.0M | ||
| Q2 25 | $-32.2M | $-40.7M | ||
| Q1 25 | $56.7M | $-48.4M | ||
| Q4 24 | $144.2M | — | ||
| Q3 24 | $-89.2M | $-41.7M | ||
| Q2 24 | $21.6M | $-80.3M | ||
| Q1 24 | $-82.6M | $-53.5M |
毛利率PRMZLAB
| Q4 25 | 45.2% | 51.0% | ||
| Q3 25 | 63.1% | 59.5% | ||
| Q2 25 | 62.4% | 60.6% | ||
| Q1 25 | 39.1% | 63.6% | ||
| Q4 24 | 48.6% | 61.5% | ||
| Q3 24 | 62.8% | 64.1% | ||
| Q2 24 | 57.6% | 64.9% | ||
| Q1 24 | 35.1% | 61.4% |
营业利润率PRMZLAB
| Q4 25 | -160.7% | -54.6% | ||
| Q3 25 | -27.7% | -42.3% | ||
| Q2 25 | -16.1% | -50.3% | ||
| Q1 25 | — | -53.3% | ||
| Q4 24 | 71.1% | -62.6% | ||
| Q3 24 | -12.2% | -66.6% | ||
| Q2 24 | 35.4% | -76.0% | ||
| Q1 24 | -126.8% | -80.7% |
净利率PRMZLAB
| Q4 25 | -136.5% | — | ||
| Q3 25 | -28.7% | -31.2% | ||
| Q2 25 | -19.8% | -37.3% | ||
| Q1 25 | 78.7% | -45.8% | ||
| Q4 24 | 167.2% | — | ||
| Q3 24 | -30.9% | -40.9% | ||
| Q2 24 | 17.0% | -80.2% | ||
| Q1 24 | -139.8% | -61.4% |
每股收益（稀释后）PRMZLAB
| Q4 25 | $-0.89 | $-0.05 | ||
| Q3 25 | $-0.62 | $-0.03 | ||
| Q2 25 | $-0.22 | $-0.04 | ||
| Q1 25 | $0.36 | $-0.04 | ||
| Q4 24 | $1.00 | $-0.09 | ||
| Q3 24 | $-0.61 | $-0.04 | ||
| Q2 24 | $0.14 | $-0.08 | ||
| Q1 24 | $-0.57 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $325.9M | $689.6M |
| 总债务越低越好 | $669.1M | — |
| 股东权益账面价值 | $1.1B | $715.5M |
| 总资产 | $2.7B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.59× | — |
8季度趋势，按日历期对齐
现金及短期投资PRMZLAB
| Q4 25 | $325.9M | $689.6M | ||
| Q3 25 | $340.6M | $717.2M | ||
| Q2 25 | $140.7M | $732.2M | ||
| Q1 25 | $200.1M | $757.3M | ||
| Q4 24 | $198.5M | $779.7M | ||
| Q3 24 | $223.1M | $616.1M | ||
| Q2 24 | $43.2M | $630.0M | ||
| Q1 24 | $38.7M | $650.8M |
总债务PRMZLAB
| Q4 25 | $669.1M | — | ||
| Q3 25 | $668.8M | — | ||
| Q2 25 | $668.4M | — | ||
| Q1 25 | $668.1M | — | ||
| Q4 24 | $667.8M | — | ||
| Q3 24 | $667.4M | — | ||
| Q2 24 | $667.1M | — | ||
| Q1 24 | $666.8M | — |
股东权益PRMZLAB
| Q4 25 | $1.1B | $715.5M | ||
| Q3 25 | $1.1B | $759.9M | ||
| Q2 25 | $1.2B | $791.7M | ||
| Q1 25 | $1.2B | $810.8M | ||
| Q4 24 | $1.2B | $840.9M | ||
| Q3 24 | $1.0B | $667.7M | ||
| Q2 24 | $1.1B | $704.2M | ||
| Q1 24 | $1.1B | $762.2M |
总资产PRMZLAB
| Q4 25 | $2.7B | $1.2B | ||
| Q3 25 | $2.6B | $1.2B | ||
| Q2 25 | $2.5B | $1.2B | ||
| Q1 25 | $2.4B | $1.2B | ||
| Q4 24 | $2.4B | $1.2B | ||
| Q3 24 | $2.5B | $985.3M | ||
| Q2 24 | $2.3B | $987.4M | ||
| Q1 24 | $2.3B | $988.4M |
负债/权益比PRMZLAB
| Q4 25 | 0.59× | — | ||
| Q3 25 | 0.60× | — | ||
| Q2 25 | 0.57× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.58× | — | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.62× | — | ||
| Q1 24 | 0.63× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.6M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $11.6M | $-26.7M |
| 自由现金流率自由现金流/营收 | 11.3% | -21.0% |
| 资本支出强度资本支出/营收 | 6.8% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $208.6M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流PRMZLAB
| Q4 25 | $18.6M | $-26.0M | ||
| Q3 25 | $198.7M | $-32.0M | ||
| Q2 25 | $-2.9M | $-31.0M | ||
| Q1 25 | $23.7M | $-61.7M | ||
| Q4 24 | $-6.0M | $-55.8M | ||
| Q3 24 | $183.0M | $-26.8M | ||
| Q2 24 | $8.6M | $-42.2M | ||
| Q1 24 | $2.8M | $-90.1M |
自由现金流PRMZLAB
| Q4 25 | $11.6M | $-26.7M | ||
| Q3 25 | $193.6M | $-35.0M | ||
| Q2 25 | $-15.6M | $-33.9M | ||
| Q1 25 | $18.9M | $-63.2M | ||
| Q4 24 | $-12.4M | $-58.4M | ||
| Q3 24 | $179.1M | $-28.2M | ||
| Q2 24 | $5.0M | $-42.9M | ||
| Q1 24 | $1.2M | $-91.1M |
自由现金流率PRMZLAB
| Q4 25 | 11.3% | -21.0% | ||
| Q3 25 | 61.4% | -30.4% | ||
| Q2 25 | -9.6% | -31.1% | ||
| Q1 25 | 26.3% | -59.9% | ||
| Q4 24 | -14.4% | -53.8% | ||
| Q3 24 | 62.1% | -27.7% | ||
| Q2 24 | 3.9% | -42.9% | ||
| Q1 24 | 2.1% | -104.5% |
资本支出强度PRMZLAB
| Q4 25 | 6.8% | 0.5% | ||
| Q3 25 | 1.6% | 2.6% | ||
| Q2 25 | 7.8% | 2.6% | ||
| Q1 25 | 6.7% | 1.5% | ||
| Q4 24 | 7.5% | 2.4% | ||
| Q3 24 | 1.3% | 1.3% | ||
| Q2 24 | 2.9% | 0.7% | ||
| Q1 24 | 2.6% | 1.1% |
现金转化率PRMZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.42× | — | ||
| Q4 24 | -0.04× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.40× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRM
| Products | $87.7M | 85% |
| Service And Other | $14.8M | 14% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
